MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
MAXCYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.30+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $138.87M
- P/E (TTM)
- –
- Dividend yield
- –
MAXCYTE, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | $15.84M | $17.01M | $18.69M | $20.34M | $21.58M | $21.05M | $21.09M | $19.79M | $18.49M | $19.17M | $18.60M | $21.53M | 51.0% | -26.6% |
| Licenses | $12.88M | $13.22M | $12.37M | $12.47M | $12.80M | $15.33M | $16.41M | – | – | – | – | – | 41.5% | +0.7% |
| Assay and other service revenue | $2.32M | $2.05M | $1.97M | – | – | – | – | – | – | – | – | – | 7.5% | – |
| Other | – | – | – | – | – | – | $1.13M | $1.13M | $973.00K | $947.00K | $897.00K | $965.40K | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $18.98M | $19.66M | $21.08M | $22.50M | $23.81M | $25.79M | $25.77M | – | – | – | – | – | 61.1% | -20.3% |
| Outside the United States | $12.08M | $12.63M | $11.95M | $11.92M | $11.94M | $11.89M | $12.86M | – | – | – | – | – | 38.9% | +1.1% |
From the segment and revenue-disaggregation notes of Maxcyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.